DexCom, Inc. (NASDAQ:DXCM) is reporting second quarter financial results on Tuesday 28th July 2020, after market close.
According to analysts surveyed by Thomson Reuters, DXCM is expected to report 2Q20 income of $ 0.35 per share from revenue of $ 415.74 million.
For the full year, analysts anticipate top line of $ 1799.51 million, while looking forward to income of $ 2.30 per share bottom line.
The Company Outlook
Full Year 2020 topline are forecasted in a range of$ 1,725.00 million ~ $ 1,775.00 million
Click Here For More Historical Outlooks Of DexCom, Inc.
Previous Quarter Performance
DexCom, Inc. revealed income for the first quarter of $ 0.44 per share, from the revenue of $ 405.10 million. The quarterly revenues gained 44.42 percent compared with the same quarter last year. Street analysts expected DexCom, Inc. to report income of $ 0.15 per share on revenue of $ 359.25 million for the first quarter. The bottom line results beat street analysts by $ 0.29 or 193.33 percent, at the same time, top line results outshined analysts by $ 45.85 million or 12.76 percent.
Historical Earnings Performance
wpDataChart with provided ID not found! wpDataTable with provided ID not found!Click Here For More Historical Earnings Of DexCom, Inc.
Stock Performance
According to the previous trading day, closing price of DXCM was $ 423.43, representing a 206.21 % increase from the 52 week low of $ 138.28 and a 5.17 % decrease over the 52 week high of $ 446.50.
The company has a market capital of $ 39.93 billion and is part of the Healthcare sector and Diagnostics & Research industry.
[stock_market_widget type=”chart” template=”basic” color=”orange” assets=”DXCM” range=”1y” interval=”1mo” axes=”true” cursor=”true” api=”yf” style=”height: 400px;”]
Recent Analyst recommendations
- On 17th June 2020, maintained by Bank of America at Buy rating, with $ 500.00 target price.
- On 9th June 2020, maintained by Raymond James at Outperform rating, with $ 395.00 target price.
Conference Call
DexCom, Inc. will be hosting a conference call at 4:30 PM eastern time on 28th July 2020, to discuss its 2Q20 financial results with the investment community. A live webcast with presentations will be available on the Internet by visiting the Company website www.dexcom.com
DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company offers its systems for ambulatory use by people with diabetes; and for use by healthcare providers. Its products include DexCom G6, a CGM system for diabetes management; DexCom G5 mobile CGM system to communicate directly to patients mobile device; DexCom G4 PLATINUM system for continuous use by adults with diabetes; and DexCom Share, a remote monitoring system.
